FDA supplemental approval: Meperidine Hydrochloride (REMS)

AI Summary

The FDA approved a supplemental Risk Evaluation and Mitigation Strategy (REMS) for meperidine hydrochloride 50 mg tablets on 18 June 2026. This is a regulatory classification action and does not contain clinical trial results, efficacy endpoints, or comparative safety data.

Plain-language summary

This is an FDA supplemental approval action establishing a Risk Evaluation and Mitigation Strategy (REMS) for meperidine hydrochloride; it is a regulatory classification, not a clinical evidence assessment.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

Clinicians and pharmacists should be aware that meperidine hydrochloride is now subject to an FDA-mandated REMS program; the specific elements of the REMS (e.g., restrictions, monitoring, or prescriber/dispenser requirements) are not detailed in this record and should be consulted in the full REMS document and product labeling.

Caveats

• This record does not contain clinical trial results, efficacy data, or comparative safety information.
• The specific REMS requirements, restrictions, and mitigation strategies are not described in this record.
• Reason for REMS addition is not stated in this source.
• No outcome data, sample size, or statistical analysis is reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.